A
Aliaksandr Druz
Researcher at National Institutes of Health
Publications - 59
Citations - 7414
Aliaksandr Druz is an academic researcher from National Institutes of Health. The author has contributed to research in topics: Epitope & Monoclonal antibody. The author has an hindex of 38, co-authored 59 publications receiving 6196 citations. Previous affiliations of Aliaksandr Druz include Vaccine Research Center & Johns Hopkins University.
Papers
More filters
Journal ArticleDOI
Structure and immune recognition of trimeric pre-fusion HIV-1 Env
Marie Pancera,Tongqing Zhou,Aliaksandr Druz,Ivelin S. Georgiev,Cinque Soto,Jason Gorman,Jinghe Huang,Priyamvada Acharya,Gwo-Yu Chuang,Gilad Ofek,Guillaume Stewart-Jones,Jonathan Stuckey,Robert T. Bailer,M. Gordon Joyce,Mark K. Louder,Nancy Tumba,Yongping Yang,Baoshan Zhang,Myron S. Cohen,Barton F. Haynes,John R. Mascola,Lynn Morris,James B. Munro,Scott C. Blanchard,Walther Mothes,Mark Connors,Peter D. Kwong +26 more
TL;DR: The structure at 3.5 Å resolution for an HIV-1 Env trimer captured in a mature closed state by antibodies PGT122 and 35O22 is reported, revealing the pre-fusion conformation of gp41, rearrangements needed for fusion activation, and defines parameters of immune evasion and immune recognition.
Journal ArticleDOI
Developmental pathway for potent V1V2-directed HIV-neutralizing antibodies.
Nicole A. Doria-Rose,Chaim A. Schramm,Jason Gorman,Penny L. Moore,Jinal N. Bhiman,Brandon J. DeKosky,Michael J. Ernandes,Ivelin S. Georgiev,Helen J. Kim,Marie Pancera,Ryan P. Staupe,Han Altae-Tran,Robert T. Bailer,Ema T. Crooks,Albert Cupo,Aliaksandr Druz,Nigel Garrett,Kam Hon Hoi,Rui Kong,Mark K. Louder,Nancy S. Longo,Krisha McKee,Molati Nonyane,Sijy O'Dell,Ryan S. Roark,Rebecca S. Rudicell,Stephen D. Schmidt,Daniel J. Sheward,Cinque Soto,Constantinos Kurt Wibmer,Yongping Yang,Zhenhai Zhang,Nisc Comparative Sequencing,James C. Mullikin,James M. Binley,Rogier W. Sanders,Ian A. Wilson,John P. Moore,Andrew B. Ward,George Georgiou,Carolyn Williamson,Salim S. Abdool Karim,Lynn Morris,Peter D. Kwong,Lawrence Shapiro,John R. Mascola +45 more
TL;DR: HIV-1 V1V2-directed neutralizing antibodies can develop relatively rapidly through initial selection of B cells with a long CDR H3, and limited subsequent somatic hypermutation, and provide important insights relevant to HIV-1 vaccine development.
Journal ArticleDOI
Broad and potent HIV-1 neutralization by a human antibody that binds the gp41–gp120 interface
Jinghe Huang,Byong H. Kang,Marie Pancera,Jeong Hyun Lee,Tommy Tong,Yu Feng,Hiromi Imamichi,Ivelin S. Georgiev,Gwo-Yu Chuang,Aliaksandr Druz,Nicole A. Doria-Rose,Leo B. Laub,Kwinten Sliepen,Marit J. van Gils,Alba Torrents de la Peña,Ronald Derking,Per Johan Klasse,Stephen A. Migueles,Robert T. Bailer,Munir Alam,Pavel Pugach,Barton F. Haynes,Richard T. Wyatt,Rogier W. Sanders,James M. Binley,Andrew B. Ward,John R. Mascola,Peter D. Kwong,Mark Connors +28 more
TL;DR: A broad and extremely potent HIV-specific monoclonal antibody, termed 35O22, which binds a novel HIV-1 envelope glycoprotein (Env) epitope, which represents a novel site of vulnerability on HIV Env, which serum analysis indicates to be commonly elicited by natural infection.
Journal ArticleDOI
Trimeric HIV-1-Env Structures Define Glycan Shields from Clades A, B and G
Guillaume Stewart-Jones,Cinque Soto,Thomas Lemmin,Thomas Lemmin,Gwo-Yu Chuang,Aliaksandr Druz,Rui Kong,Paul V. Thomas,Kshitij Wagh,Tongqing Zhou,Anna-Janina Behrens,Tatsiana Bylund,Chang W. Choi,Jack R. Davison,Ivelin S. Georgiev,M. Gordon Joyce,Young Do Kwon,Marie Pancera,Justin Taft,Yongping Yang,Baoshan Zhang,Sachin S. Shivatare,Vidya S. Shivatare,Chang-Chun D Lee,Chung-Yi Wu,Carole A. Bewley,Dennis R. Burton,Dennis R. Burton,Wayne C. Koff,Mark Connors,Max Crispin,Ulrich Baxa,Bette T. Korber,Chi-Huey Wong,Chi-Huey Wong,John R. Mascola,Peter D. Kwong +36 more
TL;DR: Crystallized fully glycosylated Env trimers from clades A, B, and G reveal a diversity in oligosaccharide affinity and a requirement for accommodating glycans among known broadly neutralizing antibodies that target the glycan-shielded trimer.
Journal ArticleDOI
Crystal structure, conformational fixation and entry-related interactions of mature ligand-free HIV-1 Env
Young Do Kwon,Marie Pancera,Priyamvada Acharya,Ivelin S. Georgiev,Emma T. Crooks,Jason Gorman,M. Gordon Joyce,Miklos Guttman,Xiaochu Ma,Sandeep Narpala,Cinque Soto,Daniel S. Terry,Yongping Yang,Tongqing Zhou,Goran Ahlsen,Robert T. Bailer,Michael Chambers,Gwo-Yu Chuang,Nicole A. Doria-Rose,Aliaksandr Druz,Mark A. Hallen,Adam Harned,Tatsiana Kirys,Mark K. Louder,Sijy O'Dell,Gilad Ofek,Keiko Osawa,Madhu Prabhakaran,Mallika Sastry,Guillaume Stewart-Jones,Jonathan Stuckey,Paul V. Thomas,Tishina Tittley,Constance Williams,Baoshan Zhang,Hong Zhao,Zhou Zhou,Bruce R. Donald,Lawrence K. Lee,Susan Zolla-Pazner,Ulrich Baxa,Arne Schön,Ernesto Freire,Lawrence Shapiro,Kelly K. Lee,James Arthos,James B. Munro,Scott C. Blanchard,Walther Mothes,James M. Binley,Adrian B. McDermott,John R. Mascola,Peter D. Kwong +52 more
TL;DR: Antigenicity-guided structural design can be used both to delineate mechanism and to fix conformation, with DS-Env trimers in virus-like-particle and soluble formats providing a new generation of vaccine antigens.